CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing—remitting multiple sclerosis
Restricted accessOtherFirst published online May, 2008
CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing—remitting multiple sclerosis
Cerebrospinal fluid (CSF) concentrations of soluble human leukocyte antigen class I (HLA-I) (sHLA-I), HLA-G (sHLA-G) and anti-apoptotic Fas (sFas) molecules were measured by enzyme linked immunosorbent assay technique in 65 relapsing—remitting (RR) MS patients classified according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. Sixty-four patients with other inflammatory neurological disorders (OIND) and 64 subjects with noninflammatory neurological disorders (NIND) served as controls. CSF concentrations were higher in RRMS and in OIND than in NIND patients for sHLA-I (P < 0.02), greater in RRMS than in OIND and in NIND for sHLA-G (P < 0.001 and P < 0.01, respectively) and lower in RRMS than in OIND and in NIND for sFas (P < 0.001 and P < 0.02, respectively). An increase in CSF levels was identified in MRI active RRMS for sHLA-I (P < 0.01) and in MRI stable RRMS for sHLA-G (P < 0.01), whereas CSF values of sFas were decreased in RRMS without Gd-enhancing lesions (P < 0.02). In MS patients with no evidence of MRI disease activity, a trend towards an inverse correlation was found between CSF concentrations of sHLA-G and sHLA-I and between CSF levels of sHLA-G and sFas. Our results indicate that enhanced CSF levels of sHLA-I antigens most likely represent an indirect manifestation of intrathecal immune activation taking place in neuroinflammation. Conversely, reciprocal fluctuations in CSF sHLA-G and sFas levels observed when MRI disease activity resolved suggest that sHLA-G could play an immunomodulatory role in MS through Fas/FasL-mediated mechanisms. Multiple Sclerosis 2008; 14: 446—454. http://msj.sagepub.com
Frohman EM , Racke MK , Raine CSMultiple sclerosis - the plaque and its pathogenesis . N Engl J Med2006; 354: 942-55.
2.
Sospedra M. , Martin R.Immunology of multiple sclerosis . Ann Rev Immunol2005; 23: 683-747.
3.
Choi C. , Benveniste ENFas ligand/Fas system in the brain: regulator of immune and apoptotic responses . Brain Res Rev2004; 44: 65-81.
4.
Papoff G. , Cascino I. , Eramo A. , Starace G. , Lynch DH , Ruberti G.An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro . J Immunol1996; 156: 4622-30.
Ciusani E. , Frigerio S. , Gelati M. , Corsini E. , Dufour A. , Nespolo A. et al. Solubile Fas (APO-1) levels in cerebrospinal fluid of multiple sclerosis patients . J Neuroimmunol1998; 82: 5-12.
7.
Heesen C. , Georghiu S. , Gbadamosi J. , Schoser BGH.CD95-mediated apoptosis and DNA fragmentation in MS . Acta Neurol Scand2000; 102: 333-6.
8.
Sharief MKImpaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis . J Neuroimmunol2000; 109: 236-43.
9.
Sharief MKHeightened intrathecal release of soluble CD137 in patients with multiple sclerosis . Eur J Neurol2002; 9: 49-54.
10.
Mahovic D. , Petravic D. , Petelin Z. , Zurak N. , Horvat G. , Hajnsek S.Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis . Clin Neurol Neurosurg2004; 106: 230-2.
11.
Inoue A. , Koh C. -S, Sakai T. , Yamazaki M. , Yanagisawa N. , Usuku K. et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy . J Neuroimmunol1997; 75: 141-6.
12.
Zipp F. , Weller M. , Calabresi PA , Frank JA , Bash CN , Dichgans J. et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis . Ann Neurol1998; 43: 116-120.
13.
Zipp F. , Otzelberger K. , Dichgans J. , Martin R. , Weller M.Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis . J Neuroimmunol1998 ; 86: 151-4.
14.
Sakai T. , Inoue A. , Koh CS , Osame M.Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy . J Interferon Cytokine Res1999; 19: 999-1004.
15.
Boylan MT , Crockard AD , McDonnell GV , McMillan SA , Hawkins SASerum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis . Immunol Lett2001; 78: 183-7.
16.
Bilinska M. , Frydecka I. , Podemski R. , Gruszka E.Fas expression on T-cells and sFas in relapsing-remitting multiple sclerosis . Acta Neurol Scand2003 ; 107: 387-93.
17.
Adamashvili I. , Kelley RE , Pressly T. , McDonald JCSoluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients . Rheumatol Int2005; 25: 491-500.
18.
Wiendl H.HLA-G in the nervous system . Hum Immunol2007 ; 68: 286-93.
19.
Contini P. , Ghio M. , Poggi A. , Filaci G. , Indiveri F. , Ferrone S. et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation . Eur J Immunol2003; 33: 125-34.
20.
Carosella ED , Moreau P. , Aractingi S. , Rouas-Freiss N.HLA-G: a shield against inflammatory aggression . Trends Immunol2001; 22: 553-5.
21.
Alvarez-Cermeño JC , Villar LM , Nocito M. , Bootello A. , Gonzales-Porque P.Intrathecal synthesis of soluble HLA class I antigens in multiple sclerosis . J Neuroimmunol1992; 36: 77-9.
22.
Filaci G. , Contini P. , Bronci S. , Gazzola P. , Lanza L. , Scudeletti M. et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients . Hum Immunol1997; 54: 54-62.
23.
Ott M. , Seidl C. , Westhoff U. , Stecker K. , Seifred E. , Fischer PA et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis . Tissue Antigens1998; 51: 301-4.
24.
Adamashvili I. , Minagar A. , Gonzalez-Toledo E. , Featherston L. , Kelley RESoluble HLA measurements in saliva and cerebrospinal fluid in caucasian patients with multiple sclerosis: a preliminary study . J Neuroinflammation2005 ; 2: 13 .
25.
Le Rond S. , Azèma C. , Krawice-Radanne I. , Durrbach A. , Guettier C. , Carosella ED et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells . J Immunol2006; 176: 3266-276.
26.
Horuzsko A. , Lenfant F. , Munn DH , Mellor ALMaturation of antigen-presenting cells is compromised in HLA-G transgenic mice . Int Immunol2001; 13: 385-94.
27.
Fuzzi B. , Rizzo R. , Criscuoli L. , Noci I. , Melchiorri L. , Scarselli B. et al. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy . Eur J Immunol2002; 32: 311-5.
28.
Fainardi E. , Granieri E. , Tola MR , Melchiorri L. , Vaghi L. , Rizzo R. et al. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA-class I molecules . J Neuroimmunol2002; 133: 151-9.
29.
Fainardi E. , Rizzo R. , Melchiorri L. , Vaghi L. , Castellazzi M. , Marzola A. et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings . J Neuroimmunol2003; 142: 149-58.
30.
Fainardi E. , Rizzo R. , Melchiorri L. , Castellazzi M. , Paolino E. , Tola MR et al. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis . Mult Scler2006; 12: 2-12.
31.
Fainardi E. , Rizzo R. , Melchiorri L. , Castellazzi M. , Govoni V. , Caniatti L. et al. Beneficial effect of interferon-β 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy . J Neuroimmunol2004; 148: 206-11.
32.
Mitsdoerffer M. , Schreiner B. , Kieseier B. , Neuhaus O. , Dichgans J. , Hartung H-P et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis . J Neuroimmunol2005 ; 159: 155-64.
33.
Wiendl H. , Feger U. , Mittelbronn M. , Jack C. , Schreiner B. , Stadelmann C. et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity . Brain2005; 128: 2689-704.
34.
McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis . Ann Neurol2001; 50: 121-27.
35.
Lublin DF , Reingold SCDefining the clinical course of multiple sclerosis: results of an international survey . Neurology1996; 46: 907-11.
36.
Poser CM , Paty DW , Scheimberger L. , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for MS: guidelines for research protocols . Ann Neurol1983; 13: 227-31.
37.
Kurtzke JFRating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS) . Neurology1983; 33: 1444-52.
38.
Rebmann V. , LeMaoult J. , Rouas-Freiss N. , Carosella ED , Grosse-Wilde H.Report of the Wet Workshop for quantification of soluble HLA-G in Essen , 2004. Hum Immunol2005; 66: 853-63.
39.
Le Friec G. , Laupeze B. , Fardel O. , Sebti Y. , Pangault C. , Guilloux V. et al. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes . Hum Immunol2003; 64: 752-61.
40.
Inostroza J. , Munoz P. , Espinoza R. , Millaqueo L. , Diaz P. , Leiva L. et al. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tuberculosis . Hum Immunol1994; 40: 179-84.
41.
Okuda Y. , Apatoff BR , Posnett DNApoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity in multiple sclerosis . J Neuroimmunol2006; 171: 163-70.
42.
Feger U. , Tolosa E. , Huang Y. -H, Waschbisch A. , Biedermann T. , Melms A. et al. HLA-G expression defines a novel regulatory T cell subset present in human peripheral blood and sites of inflammation . Blood2007; 110: 568-77.
43.
Miller DH , Barkhof F. , Nauta JJP.Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis . Brain1993 ; 116: 1077-94.
44.
LeMaoult J. , Le Discorde M. , Rouas-Freiss N. , Moreau P. , Menier C. , McCluskey J. et al. Biology and functions of human leukocyte antigen-G in health and sickness . Tissue Antigens2003; 62: 273-84.
